Umeclidinium bromide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Umeclidinium bromide
Umeclidinium bromide.svg
Umeclidinium bromide 3D.png
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
  • US: C (Risk not ruled out)
Routes of
Inhalation (DPI)
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding~89%[1]
MetabolismHepatic (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.166.375 Edit this at Wikidata
Chemical and physical data
Molar mass508.500 g·mol−1
3D model (JSmol)

Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[2][3] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[4]

External links[edit]


  1. ^ a b "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
  2. ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
  3. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  4. ^ "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Retrieved 11 July 2020.